MDR.AX MedAdvisor (ASX) A$0.022 pre-market 20 Mar 2026: Oversold bounce targets A$0.035

MDR.AX stock trades at A$0.022 in pre-market trade on 20 Mar 2026, a level near the 52-week low A$0.019 that flags a possible oversold bounce. Volume is light at 59,301 shares versus an average of 1,383,220, but short-term technicals and stretched valuation metrics suggest a mean-reversion setup. We outline catalysts, risks, and a trade plan that targets a conservative bounce to A$0.035. This analysis uses company metrics, sector context and Meyka AI tools to frame price action for ASX-listed MedAdvisor Limited

MDR.AX stock: recent trading and catalyst

MedAdvisor Limited (MDR.AX) opened pre-market at A$0.021 and sits at A$0.022 now. The stock has fallen -90.43% YTD and is trading near its year low A$0.019, which creates the oversold backdrop. Recent earnings released on 26 Feb 2026 showed continued losses with EPS -0.11 and limited cash per share A$0.017, weighing on sentiment.

Corporate catalysts that could trigger a bounce include any positive update on recurring revenue growth for the MedAdvisor platform or a capital raise that eases short-term liquidity pressure. Absent such news, volume and market-wide healthcare flows will likely dictate moves on the ASX.

Fundamentals and valuation snapshot for MDR.AX stock

MedAdvisor reports negative earnings and an adverse price-to-earnings metric with PE -0.20 and EPS -0.11, reflecting recent losses. Price-to-sales is modest at 0.22, and enterprise value to sales is 0.33, implying the market prices limited near-term revenue risk.

Balance-sheet metrics show cash per share A$0.017 and working capital around A$16,602,390, but shareholders equity per share is negative. The healthcare sector average PE is 27.15, so MDR.AX sits well below sector multiples, highlighting both risk and potential upside if execution improves.

Technical setup: oversold bounce thesis

Price sits below the 50-day average A$0.0275 and far below the 200-day average A$0.0673, signaling a stretched downtrend that can produce short squeezes. On low relative volume (relVolume 0.04), small buy orders can lift price quickly.

For an oversold bounce play we watch intraday resistance at A$0.030 and a near-term target at A$0.035. A protective stop below A$0.019 limits downside. Traders should confirm any bounce with rising volume and improvement in bid size before increasing position.

Meyka AI grade and MDR.AX stock forecast

Meyka AI rates MDR.AX with a score of 69.37 out of 100 and assigns a Grade B, Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus.

Meyka AI’s forecast model projects a short-term bounce target of A$0.035, implying an upside of 59.09% from the current A$0.022. The model also shows a conservative downside risk to A$0.012 if liquidity worsens. Forecasts are model-based projections and not guarantees.

Risk factors and sector context for MDR.AX stock

Key risks include ongoing negative profitability, limited cash per share A$0.017, and thin trading liquidity (avg volume 1,383,220). Negative EPS and a negative book value per share raise solvency and dilution concerns.

Healthcare sector flows are down YTD and the sector has lagged broader markets. A recovery in tech-driven health solutions or renewed institutional interest would be needed to materially lift valuation multiples for MedAdvisor on the ASX.

Trading plan, targets and valuation outlook

For an oversold bounce strategy we recommend a small, staged position on confirmed volume pickup. Target A$0.035 for a first take-profit and A$0.050 as an optimistic secondary target if fundamentals improve. Use a hard stop at A$0.019 to limit risk.

Valuation remains speculative: a normalized price-to-sales multiple near sector norms would imply materially higher levels, but that requires durable margin improvements and revenue growth. Monitor cash runway and any capital markets activity closely.

Final Thoughts

MDR.AX stock at A$0.022 pre-market on 20 Mar 2026 presents a classic oversold bounce setup: shallow float, extremely low price versus moving averages, and a stretched negative sentiment backdrop. Our short-term plan targets A$0.035 for an initial exit and A$0.050 as a secondary target if volume and fundamentals confirm a recovery. Meyka AI rates the stock 69.37/100 (Grade B, HOLD) and models a 59.09% upside to the A$0.035 bounce target, while flagging downside to A$0.012 on liquidity stress. Traders must limit exposure, use a stop near A$0.019, and watch cash metrics and any revenue updates. For longer-term investors, improvement in recurring revenue and margin expansion would be required before revising a HOLD stance. Sources: company filings and platform data, plus Meyka AI-powered market analysis

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.